MRNA Oct 2023 90.000 put
| Previous close | 0.6100 |
| Open | 0.6500 |
| Bid | 0.4300 |
| Ask | 0.4700 |
| Strike | 90.00 |
| Expiry date | 2023-10-20 |
| Day's range | 0.4800 - 0.9400 |
| Contract range | N/A |
| Volume | |
| Open interest | 3.08k |
- Yahoo Finance Video
Moderna CEO on combo Covid, flu vaccine moving to next trial phase
A lot of Americans are planning on getting both a flu shot and Covid booster this fall. But Moderna (MRNA) has been working on a combination flu and Covid vaccine, so patients only need to get one shot instead of two. The biotech company announced that the combination vaccine will be moving on to its final trial after positive results from its early-stage trial. The company is hoping to have regulatory approval for the shot in 2025. Moderna CEO Stéphane Bancel tells Yahoo Finance Live that when it comes to it's current Covid vaccine, there has been "strong demand." Bancel expects to continue to see sales of the Covid vaccine into 2025 and "re-acceleration of sales" when the combination vaccine launches. When it comes to the current updated Covid booster, Bancel thinks that pharmacy chains may have underestimated demand for the shot and how quickly people would want it. For more expert insight and the latest market action, click here to watch this full episode of Yahoo Finance Live.
Yahoo FinanceNovavax expects COVID-19 boosters to be available next week
Novavax gets green light from FDA, awaits CDC recommendation for booster COVID doses.
ZacksAlexandria (ARE) Expedites Delivery of Moderna's New HQ
Alexandria (ARE) to hand over the new global headquarters and core R&D operations center to Moderna in November 2023. ARE will benefit from the project's incremental annual net operating income.
